135 related articles for article (PubMed ID: 342295)
21. [Clinical tests of the therapeutic effect of a new difluocortolone valerate cream].
Gatti JC; Cardama E; Pizzariello GE; Luppi MS
Z Hautkr; 1976; 51 Suppl 1():33-6. PubMed ID: 795185
[TBL] [Abstract][Full Text] [Related]
22. Blanching activities of betamethasone formulations. The effect of dosage form on topical drug availability.
Smith EW; Meyer E; Haigh JM
Arzneimittelforschung; 1990 May; 40(5):618-21. PubMed ID: 2383308
[TBL] [Abstract][Full Text] [Related]
23. [Comparative study on the efficacy of diflucortolone valerate in the psoriasis plaque test (author's transl)].
Lofferer O; Reckers R
Arzneimittelforschung; 1978; 28(4):703-5. PubMed ID: 373772
[TBL] [Abstract][Full Text] [Related]
24. Are generic formulations equivalent to trade name topical glucocorticoids?
Stoughton RB
Arch Dermatol; 1987 Oct; 123(10):1312-4. PubMed ID: 3662563
[TBL] [Abstract][Full Text] [Related]
25. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.
Medansky RS; Bressinck R; Cole GW; Deeken JH; Ellis CN; Guin JD; Herndon JH; Lasser AE; Leibsohn E; Menter MA
Cutis; 1988 Nov; 42(5):480-5. PubMed ID: 3058398
[TBL] [Abstract][Full Text] [Related]
26. Diflucortolone valerate (Nerisona): a comparative vasoconstriction test in artificially induced hyperemia of the skin.
Reckers R; Wendt H
Clin Ther; 1980; 3(3):190-3. PubMed ID: 7459929
[TBL] [Abstract][Full Text] [Related]
27. The evaluation of a novel corticosteroid formulation, fluocinonide in "FAPG" base, in the blanching test.
Coldman MF; Lockerbie L; Laws EA
Br J Dermatol; 1971 Dec; 85(6):573-6. PubMed ID: 4947552
[No Abstract] [Full Text] [Related]
28. [Clinical trial of fluocortin butylester in a double-blind contralateral comparison versus fluocortolone and hydrocortisone acetate (author's transl)].
Reckers R
Arzneimittelforschung; 1977; 27(11a):2240-4. PubMed ID: 341901
[TBL] [Abstract][Full Text] [Related]
29. [Experimental toxicity studies on fluocortin butylester in the forms of pure active principle, ointment, fatty ointment and cream in animals (author's transl)].
Günzel P; Siegmund F; Bhargava AS; El Etreby MF; Lang R; Poggel HA; Schöbel C; Schuppler J; Staben P
Arzneimittelforschung; 1977; 27(11a):2217-21. PubMed ID: 580031
[No Abstract] [Full Text] [Related]
30. [The use of difluocortolone valerate in various dermatoses].
Ocampo FA
Z Hautkr; 1976; 51 Suppl 1():17-9. PubMed ID: 795180
[TBL] [Abstract][Full Text] [Related]
31. Objective determination of the bioavailability of dermocorticoids--influence of the formulation.
Poelman MC; Leveque JL; Le Gall F
Br J Dermatol; 1984 Jul; 111 Suppl 27():158-62. PubMed ID: 6743548
[TBL] [Abstract][Full Text] [Related]
32. [Use of 0.3% diflucortolone valerate in the topical treatment of steroid-sensitive dermatitis].
Jucci A; Fideli D; Speziali A
G Ital Dermatol Venereol; 1986; 121(6):LXXVII-LXXX. PubMed ID: 3549546
[No Abstract] [Full Text] [Related]
33. Development and evaluation of ointment and cream vehicles for a new topical steroid, fluclorolone acetonide.
Malone T; Haleblian JK; Poulsen BJ; Burdick KH
Br J Dermatol; 1974 Feb; 90(2):187-95. PubMed ID: 4819137
[No Abstract] [Full Text] [Related]
34. [Comparative studies in man on the percutaneous absorption of diflucortolone valerate, betamethasone-17-valerate, beclomethasone dipropionate and fluocinolone acetonide].
Täuber VU; Amin M; Fuchs P; Speck U
Arzneimittelforschung; 1976; 26(7b):1492-5. PubMed ID: 1036945
[TBL] [Abstract][Full Text] [Related]
35. [Clinical research on a new corticoid-containing topical drug].
Sturde HC
Z Hautkr; 1976 Aug; 51(16):673-8. PubMed ID: 969808
[TBL] [Abstract][Full Text] [Related]
36. [Local treatment of eczema with flupamesone. Double blind study with fluocinolone acetonide].
Rodríguez Moreno T; Rodríguez Cañas T
Rev Clin Esp; 1976 Aug; 142(3):255-60. PubMed ID: 788066
[No Abstract] [Full Text] [Related]
37. [Topical treatment of various dermatoses with 0.1% difluocartolone valerate with 1% chlorquinaldol (cream)].
Ogarrio González SR
Prensa Med Mex; 1977; 42(1-2):103-5. PubMed ID: 896646
[No Abstract] [Full Text] [Related]
38. Temetex in the treatment of steroid-responsive dermatoses.
Bergson VS; Franklin WH
J Int Med Res; 1977; 5(1):33-6. PubMed ID: 138609
[TBL] [Abstract][Full Text] [Related]
39. Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels.
Barry BW; Woodford R
Br J Dermatol; 1974 Sep; 91(3):323-38. PubMed ID: 4611447
[No Abstract] [Full Text] [Related]
40. [Clinical testing of a 0.1 percent difluocortolone valerianate ointment in various chronic dermatoses].
Germes LEAL O; Hernández Grazia J
Prensa Med Mex; 1977; 42(3-4):179-82. PubMed ID: 335381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
